title: [High dose chemotherapy and germ cell tumor].
abstract: Germ cell tumors are cured by cisplatin-based chemotherapy and secondary surgery. Patients with initial poor response to chemotherapy and relapsed disease patients have poor prognosis. Among different therapeutic approaches high dose chemotherapy with hematopoietic stem cell support has been studied. Despite the existence of a number of phase II trials and several well-conducted phase III trials, this approach is neither a standard nor an option in the setting of first line and first salvage treatment. A randomized phase III trial has recently been initiated and patients with relapsed disease should be offered to participate in the trial. Several selected indications could be discussed in further lines of treatment.
authors.affiliation: Institut Gustave-Roussy, département de médecine oncologique, Villejuif, France. christophe.massard@igr.fr
authors.forename: Christophe
authors.initials: C
authors.lastname: Massard
authors.forename: Aude
authors.initials: A
authors.lastname: Fléchon
authors.forename: Karim
authors.initials: K
authors.lastname: Fizazi
authors.forename: Jean-Pierre
authors.initials: JP
authors.lastname: Droz
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage*; D002945:Cisplatin / Q000008:administration & dosage; D017326:Clinical Trials, Phase III as Topic; D006801:Humans; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy; D009373:Neoplasms, Germ Cell and Embryonal / Q000188:drug therapy* / Q000401:mortality; D017239:Paclitaxel / Q000008:administration & dosage; D011379:Prognosis; D016032:Randomized Controlled Trials as Topic; D016879:Salvage Therapy / Q000379:methods
chemical_list: D017239:Paclitaxel; D002945:Cisplatin